Optometrists in Kalamazoo, MI Accepting Medicare
48 Optometrists found. Showing 41 - 48
 Rx Optical Optometrist Medicare: Not Enrolled in Medicare Practice Location: 5465 Gull Rd, Kalamazoo, MI 49048 Phone: 269-349-7631 Fax: 269-349-3639 |
Rx Optical Laboratories, Inc. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 601 John St Ste M-261, Kalamazoo, MI 49007 Phone: 269-553-1848 |
 Dr. August Andre Krymis Jr., O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 4425 W Main St, Kalamazoo, MI 49006 Phone: 369-345-4425 Fax: 269-345-4435 |
 Dr. Ariel Lynne Goodman, OD Optometrist Medicare: May Accept Medicare Assignments Practice Location: 5465 Gull Rd, Kalamazoo, MI 49048 Phone: 269-349-7631 Fax: 269-349-3639 |
Joellen Maurer, OD Optometrist Medicare: Medicare Enrolled Practice Location: 5349 W Main St, Kalamazoo, MI 49009 Phone: 269-349-7627 |
Rx Optical Laboratories, Inc. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3013 Oakland Dr, Kalamazoo, MI 49008 Phone: 269-382-3453 |
Dr. Christopher Michaels Pavone, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 4431 Hemmingway Dr, Kalamazoo, MI 49009 Phone: 847-404-3020 |
Rx Optical Laboratories, Inc. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 5465 Gull Rd, Kalamazoo, MI 49048 Phone: 269-349-7631 |
News Archive
African Broadcast Media partnership against HIV/AIDS plans 24-country campaign
The African Broadcast Media Partnership Against HIV/AIDS, which includes 37 major public and private broadcast companies, on Dec. 1 will launch the first multiyear, pan-African campaign across 24 countries to raise public awareness about HIV/AIDS, Reuters reports.
Interferon combined with ribavirin treatment is effective for children with chronic Hepatitis C virus
Nearly half of 118 children with chronic Hepatitis C virus (HCV) treated with a combination of interferon-alpha-2b and an optimized dose of ribavirin achieved sustained viral response, and side effects were generally mild.
Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial
Human Genome Sciences, Inc. and Aegera Therapeutics, Inc. today announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors.
House Democrats to open hearings amid controversy over finances, public plan
"House Democrats are pushing forward with a partisan health care bill even as a key Senate Democrat labors to achieve an elusive bipartisan compromise on President Barack Obama's top legislative priority," The Associated Press reports.
› Verified 9 days ago
Physical Therapists
Occupational Therapists
Speech-Language Pathologists
Chiropractors
Optometrists
Audiologists
Podiatrists